Repository logo
 
Publication

Intracameral Bevacizumab as an Adjunct to Trabeculectomy: a 1-Year Prospective, Randomised Study

2014Journal article Open access
Simple item page
dc.contributor.authorVandewalle, E
dc.contributor.authorAbegão Pinto, L
dc.contributor.authorBergen, T
dc.contributor.authorSpielberg, L
dc.contributor.authorFieuws, S
dc.contributor.authorMoons, L
dc.contributor.authorSpileers, W
dc.contributor.authorZeyen, T
dc.contributor.authorStalmans, I
dc.date.accessioned2021-08-11T14:14:12Z
dc.date.available2021-08-11T14:14:12Z
dc.date.issued2014
dc.description.abstractAims: To investigate the efficacy and safety of a single intracameral bevacizumab injection to improve the outcome of trabeculectomy. Methods: A 12-month, prospective, randomised, double-masked, placebo-controlled trial. Patients with medically uncontrolled open-angle glaucoma scheduled for a primary trabeculectomy were recruited and randomised to receive 50 µL of either bevacizumab (1.25 mg) or placebo (balanced salt solution) peroperatively. Absolute success was defined as intraocular pressure (IOP) ≤18 mm Hg and >5 mm Hg with at least 30% reduction from baseline and no loss of light perception. Success through the use of additional medical and/or surgical IOP-lowering treatments was defined as qualified success. Results: 138 patients completed a 12-month follow-up, 69 of whom were in the bevacizumab treated group. IOP at 1 year postoperatively was significantly lower than baseline (placebo: 25.6±9.9 mm Hg vs 11.5±3.9 mm Hg, p<0.01; bevacizumab: 24.8±8.1 mm Hg vs 11.9±3.8 mm Hg, p<0.01), with no difference between treatment groups (p=0.69). However, absolute success was higher in the bevacizumab group (71% vs 51%, p=0.02), with the need for IOP-lowering interventions (needlings) being lower in this group (12% vs 33%, p=0.003). Complication rates were low and comparable between groups. Conclusions: Peroperative administration of intracameral bevacizumab significantly reduces the need for additional interventions during the follow-up of patients undergoing trabeculectomy.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationBr J Ophthalmol. 2014 Jan;98(1):73-8.pt_PT
dc.identifier.doi10.1136/bjophthalmol-2013-303966pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.17/3807
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherBMJpt_PT
dc.subjectHSAC OFTpt_PT
dc.subjectAgedpt_PT
dc.subjectAngiogenesis Inhibitors / administration & dosagept_PT
dc.subjectAngiogenesis Inhibitors / adverse effectspt_PT
dc.subjectAntibodies, Monoclonal, Humanized / administration & dosagept_PT
dc.subjectAntibodies, Monoclonal, Humanized / adverse effectspt_PT
dc.subjectBevacizumabpt_PT
dc.subjectChemotherapy, Adjuvantpt_PT
dc.subjectFemalept_PT
dc.subjectDouble-Blind Methodpt_PT
dc.subjectMalept_PT
dc.subjectGlaucoma, Open-Angle / drug therapypt_PT
dc.subjectGlaucoma, Open-Angle / surgerypt_PT
dc.subjectHumanspt_PT
dc.subjectKaplan-Meier Estimatept_PT
dc.subjectMiddle Agedpt_PT
dc.subjectProspective Studiespt_PT
dc.subjectTime Factorspt_PT
dc.subjectTrabeculectomypt_PT
dc.titleIntracameral Bevacizumab as an Adjunct to Trabeculectomy: a 1-Year Prospective, Randomised Studypt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage78pt_PT
oaire.citation.startPage73pt_PT
oaire.citation.titleBritish Journal of Ophthalmologypt_PT
oaire.citation.volume98pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
BJO 2014 73.pdf
Size:
542.37 KB
Format:
Adobe Portable Document Format
Download

Collections

OFT - Artigos